This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, Hospices Civils De Lyon. Active years: 2017.
Company Filing History:
1 out of 39 
1 out of 5,383 
1 out of 46 
Years Active: 2017
Title: The Innovative Contributions of Alain Kfoury
Introduction
Alain Kfoury is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on enhancing the efficacy of chemotherapy agents by targeting specific molecular interactions.
Latest Patents
Kfoury holds a patent titled "Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction." This patent describes a method for selecting in vitro compounds that can potentiate the effects of DNA damage-inducing chemotherapy agents for cancer treatment. The method involves selecting compounds that inhibit the interaction between MyD88 and ERK MAP Kinase. He has 1 patent to his name.
Career Highlights
Throughout his career, Alain Kfoury has worked with esteemed institutions such as Centre Léon Bérard and Université Claude Bernard – Lyon 1. His research has contributed to advancements in cancer therapies, showcasing his commitment to improving patient outcomes.
Collaborations
Kfoury has collaborated with notable colleagues, including Isabelle Coste-Invernizzi and Serge Lebecque. These partnerships have further enriched his research and development efforts in the field of oncology.
Conclusion
Alain Kfoury's innovative work in cancer treatment exemplifies the impact of targeted research and collaboration in advancing medical science. His contributions continue to inspire future developments in the fight against cancer.